10 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases (PDE4NPD)
Date du début: 1 mars 2014, Date de fin: 28 févr. 2018,
This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs) in the fight for neglected parasitic diseases (NPD). It will establish a drug discovery platform, PDE4NPD, that combines phenotypic screening with efficient target-centric drug discovery, including target validation, various strategies for compound screening, ...
Voir le projet
11
Participants partenaires
TERMINÉ
Molecular basis of the outer membrane permeability (TRANSLOCATION)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat ...
Voir le projet
28
Participants partenaires
TERMINÉ
Kinetics for Drug Discovery (K4DD) (K4DD)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
...inity and selectivity. For us, integration means analyzing the kinetic behavior of different targets (GPCRs, kinases, proteases) across the three work packages. The partners in the consortium are European key players: they elucidate(d) structures of GPCRs and kinases, are at the forefront of bioanalytical techniques, e.g. surface plasmon resonance, are world-leaders in PKPD modeling, and bring the ...
Voir le projet
21
Participants partenaires
TERMINÉ
MOLECULAR BASIS OF ANTIBIOTIC TRANSLOCATION (Translocation)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
Multidrug resistant bacteria are now ubiquitous in both hospitals and the larger community. Drug-resistant pathogens are becoming increasingly pervasive, for example, the resurrection of tuberculosis provides one ominous example highlighting the risk associated with evolved drug resistance. Moreover, many pharmaceutical companies abandoned this field and no truly novel active antibacterial compoun ...
Voir le projet
11
Participants partenaires
TERMINÉ
Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population (EURHYTHDIA)
Date du début: 1 oct. 2011, Date de fin: 30 juin 2017,
...ght disturb the circadian clocks and severely disrupt endocrine and metabolic processes, contributing to an increased risk of type 2 diabetes/obesity. Especially shift workers constituting 20% of the European working population are affected by this prob-lem. Until now only few studies investigating circadian rhythm disturbances in the context of type 2 diabetes/obesity have been conducted in man. ...
Voir le projet
17
Participants partenaires
TERMINÉ
Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention (CVGENES-AT-TARGET)
Date du début: 1 oct. 2013, Date de fin: 31 mars 2017,
Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atheroscle ...
Voir le projet
13
Participants partenaires
TERMINÉ
New Medicines for Trypanosomatidic Infections (NMTRYPI)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2017,
The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people’s lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The New Medicine for T ...
Voir le projet
14
Participants partenaires
TERMINÉ
Hanging Drop based automated and parallelized cell technology platform for production and testing (DropTech)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2017,
Cell-based screenings are today a necessary tool for all types of clinical development and/or market approval of new drugs and chemicals. The major change in the last decade is a shift towards more physiologically relevant yet complex and sensitive cell models, like stem cells, and more recently, the shift to human induced pluripotent cells. Stem-cell technology has the potential to revolutionize ...
Voir le projet
4
Participants partenaires
TERMINÉ
European Bank for induced pluripotent Stem Cells (EBISC)
Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,
...g and regenerative medicine, and scholars in law and ethics. The main facility will be at the Babraham Research Campus (Cambridge, UK) and will undertake cell expansion, QC and characterisation. The European Cell Culture Collection (ECACC) of Public Health England (Department of Health, UK) will coordinate cell line distribution. The Fraunhofer IBMT (Saarbrücken, Germany) will provide comprehensi ...
Voir le projet
30
Participants partenaires
TERMINÉ
Natural products from marine fungi for the treatment of cancer (MARINE FUNGI)
Date du début: 1 mai 2011, Date de fin: 30 avr. 2014,
The aim of MARINE FUNGI is the demonstration of sustainable exploitation of marine natural resources providing appropriate culture conditions for the underutilised group of marine fungi, thus enabling efficient production of marine natural products in the laboratory and also in large scale cultures, avoiding harm to the natural environment. The focus of MARINE FUNGI are new anti-cancer compounds T ...
Voir le projet